Conference abstract
Benefits of bi-antibiotherapy in the treatment of neonatal bacterial infection at Laquintinine hospital in Douala, Cameroon
Pan African Medical Journal - Conference Proceedings. 2023:16(11).15
Mar 2023.
doi: 10.11604/pamj-cp.2023.16.11.1869
Archived on: 15 Mar 2023
Contact the corresponding author
Keywords: Therapeutic recommendations, neonatal infection, Cameroon
Oral presentation
Benefits of bi-antibiotherapy in the treatment of neonatal bacterial infection at Laquintinine hospital in Douala, Cameroon
Julien Mang Mani1, Mbono Betoko Ritha1,2, Cécile Okala Ebongue1,3, Charlotte Eposse Ekoube1,2, Grace Dallé Ngondi1,2, Patricia Epee Eboum-bou1,4, Hassanatou Iyawa Ousmanou1,2, Enyama Dominique5,6, Olivia Evindi Abomo3, Paul Olivier Koki Ndombo7,8, Daniele Mangamba Kedi Koum1,9, Calixte Ida Penda1,2,3,&
1Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon, 2Laquintinie Hospital of Douala, Douala, Cameroon, 3Douala General Hospital, Douala, Cameroun, 4Bonassama District Hospital, Douala, Cameroon, 5Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon, 6Douala Gynaeco-Obstetric and Paediatric Hospital, Douala, Cameroon, 7Mother & Child Centre (MCH), Chantal Biya Foundation, Yaoundé, Cameroon, 8Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon, 9Deido District Hospital, Douala, Cameroon
&Corresponding author
Introduction: Neonatal infection (NNI) is a major cause of morbidity and mortality in newborns (NB) in resource-limited settings. Antibiotic therapy is the mainstay of newborn care and survival. Our work aimed to evaluate the use of a dual therapy recommended by the High Authority for Health compared to the current triple therapy used in the neonatology department of the Laquintinine Hospital of Douala (LHD).
Methods: a cross-sectional study was conducted from January 1 to March 31, 2020, in the neonatology department of the LHD. Any full-term or premature neonate of gestational age ≥ 34th week with anamnestic and/or clinical criteria for NNI was included. Newborns suspected of NNI were divided into 3 treatment groups administered according to NNI severity criteria: Protocol 1 (Ampicillin/Gentamycin); protocol 2 according to the High Authority for Health (HAS) (Cefotaxime/Gentamycin) and protocol 3 (Cefotaxime/Ampicillin/Tobramycin) in force in this department. We evaluated the duration of hospitalization, the clinical evolution, and the kinetics of CRP in the 2 groups. A p-value ≤ 0.05 was statistically significant.
Results: we included 320 newborns admitted for NNI. Newborns 0-7 days old accounted for 94.1% of cases. NB under Protocol 2 had a longer length to stay than those who received Protocol 3 (p=0.015) and more children were significantly cured in Protocol 2 than in Protocol 3 (p=0.022). More than half of the NB with a positive initial CRP obtained a negative CRP after 72 h of treatment regardless of the protocol used.
Conclusion: dual therapy, a therapeutic recommendation of the High Authority of Health (HAS) has made it possible to obtain a cure rate of more than 50%, a favorable biological response but with a longer hospital stay for a newborn baby’s gestational age ≥ 34 weeks.
Benefits of bi-antibiotherapy in the treatment of neonatal bacterial infection at Laquintinine hospital in Douala, Cameroon
Julien Mang Mani1, Mbono Betoko Ritha1,2, Cécile Okala Ebongue1,3, Charlotte Eposse Ekoube1,2, Grace Dallé Ngondi1,2, Patricia Epee Eboum-bou1,4, Hassanatou Iyawa Ousmanou1,2, Enyama Dominique5,6, Olivia Evindi Abomo3, Paul Olivier Koki Ndombo7,8, Daniele Mangamba Kedi Koum1,9, Calixte Ida Penda1,2,3,&
1Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon, 2Laquintinie Hospital of Douala, Douala, Cameroon, 3Douala General Hospital, Douala, Cameroun, 4Bonassama District Hospital, Douala, Cameroon, 5Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon, 6Douala Gynaeco-Obstetric and Paediatric Hospital, Douala, Cameroon, 7Mother & Child Centre (MCH), Chantal Biya Foundation, Yaoundé, Cameroon, 8Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon, 9Deido District Hospital, Douala, Cameroon
&Corresponding author
Introduction: Neonatal infection (NNI) is a major cause of morbidity and mortality in newborns (NB) in resource-limited settings. Antibiotic therapy is the mainstay of newborn care and survival. Our work aimed to evaluate the use of a dual therapy recommended by the High Authority for Health compared to the current triple therapy used in the neonatology department of the Laquintinine Hospital of Douala (LHD).
Methods: a cross-sectional study was conducted from January 1 to March 31, 2020, in the neonatology department of the LHD. Any full-term or premature neonate of gestational age ≥ 34th week with anamnestic and/or clinical criteria for NNI was included. Newborns suspected of NNI were divided into 3 treatment groups administered according to NNI severity criteria: Protocol 1 (Ampicillin/Gentamycin); protocol 2 according to the High Authority for Health (HAS) (Cefotaxime/Gentamycin) and protocol 3 (Cefotaxime/Ampicillin/Tobramycin) in force in this department. We evaluated the duration of hospitalization, the clinical evolution, and the kinetics of CRP in the 2 groups. A p-value ≤ 0.05 was statistically significant.
Results: we included 320 newborns admitted for NNI. Newborns 0-7 days old accounted for 94.1% of cases. NB under Protocol 2 had a longer length to stay than those who received Protocol 3 (p=0.015) and more children were significantly cured in Protocol 2 than in Protocol 3 (p=0.022). More than half of the NB with a positive initial CRP obtained a negative CRP after 72 h of treatment regardless of the protocol used.
Conclusion: dual therapy, a therapeutic recommendation of the High Authority of Health (HAS) has made it possible to obtain a cure rate of more than 50%, a favorable biological response but with a longer hospital stay for a newborn baby’s gestational age ≥ 34 weeks.
